08 July 2013
EMA/PRAC/417172/2013
Pharmacovigilance Risk Assessment Committee (PRAC)

Pharmacovigilance Risk Assessment Committee (PRAC)

Draft agenda of the meeting on 8-11 July 2013

Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures
(Items 2 and 3 of the PRAC agenda)

A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety related referrals please see:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid=WC0b01ac05800240d0

Signals assessment and prioritisation
(Item 4 of the PRAC agenda)

A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine's benefits and risks.
The presence of a safety signal does not mean that a medicine has caused the reported adverse event. The adverse event could be a symptom of another illness or caused by another medicine taken by the patient. The evaluation of safety signals is required to establish whether or not there is a causal relationship between the medicine and the reported adverse event.
The evaluation of safety signals may not necessarily conclude that the medicine caused the adverse event in question. In cases where a causal relationship is confirmed or considered likely, regulatory action may be necessary and this usually takes the form of an update of the summary of product characteristics and the package leaflet.

Risk Management Plans (RMPs)
(Item 5 of the PRAC agenda)

The RMP describes what is known and not known about the side effects of a medicine and states how these risks will be prevented or minimised in patients. It also includes plans for studies and other activities to gain more knowledge about the safety of the medicine and risk factors for developing side effects.
RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available.

Assessment of Periodic Safety Update Reports (PSURs)

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom

Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7051
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

(Item 6 of the PRAC agenda)

A PSUR is a report providing an evaluation of the benefit-risk balance of a medicine, which is submitted by marketing authorisation holders at defined time points following a medicine's authorisation.
PSURs summarises data on the benefits and risks of a medicine and includes the results of all studies carried out with this medicine (in the authorised and unauthorised indications).

Post-authorisation Safety Studies (PASS)
(Item 7 of the PRAC agenda)

A PASS is a study of an authorised medicinal product carried out to obtain further information on its safety, or to measure the effectiveness of risk management measures. The results of a PASS help regulatory agencies to evaluate the safety and benefit-risk profile of a medicine.

Product related pharmacovigilance inspections
(Item 8 of the PRAC agenda)

Inspections carried out by regulatory agencies to ensure that marketing authorisation holders comply with their pharmacovigilance obligations.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

Chair: June Raine – Vice-Chair: Almath Spooner

8 July 2013, 13:00 – 19:00, room 3/A

9 July 2013, 08:30 – 19:00, room 3/A

10 July 2013, 08:30– 19:00, room 3/A

11 July 2013, 08:30 – 16:00, room 3/A

Organisational, regulatory and methodological matters (ORGAM)

25 July 2013, 09:30 - 10:30, room 2/C, via teleconference

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

1.2. Adoption of agenda of the meeting on 8-11 July 2013

Status: *for adoption*

Document: PRAC Agenda Rev.3 due for publication on 8 July 2013

1.3. Minutes of the previous PRAC meeting on 10-13 June 2013

Status: *for adoption*

Document: PRAC Final Minutes due for publication by 21 July 2013

2. EU Referral Procedures for Safety Reasons: Urgent EU Procedures

2.1. Newly triggered procedures

2.1.1. **Hydroxyethyl starch** (**HES**), **solutions for infusion** (NAP)

- Review of the benefit-risk balance following notification by the United Kingdom of a referral under Article 107i of Directive 2001/83/EC

Status*: for discussion and adoption of a list of questions and procedure timetable*

Regulatory details:

PRAC Rapporteur: *to be appointed*
PRAC Co-Rapporteur: *to be appointed*

2.2. Ongoing Procedures

None

2.3. Procedures for finalisation

None

2.4. Planned public hearings

None

3. EU Referral Procedures for Safety Reasons: Other EU Referral Procedures

3.1. Newly triggered Procedures

3.1.1. **Zolpidem** (NAP)

- Review of the benefit-risk balance following notification by Italy of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

***Status**: for discussion and adoption of a list of questions and procedure timetable*

Regulatory details:

PRAC Rapporteur: *to be appointed*
PRAC Co-Rapporteur: *to be appointed*

3.2. Ongoing Procedures

3.2.1. **Combined hormonal contraceptives**:

desogestrel, **gestodene, norgestimate**, **etonogestrel, drospirenone**, **dienogest**, **chlormadinone**, **norgestimate** (NAP), **nomegestrol acetate / estradiol – IOA** (CAP), **ZOELY** (CAP), **norelgestromin / ethinylestradiol** - **EVRA** (CAP)

- Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

***Status:** for discussion and adoption of list of outstanding issues*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)
PRAC Co-Rapporteur: Evelyne Falip (FR)

3.2.2. **Diacerein** (NAP)

- Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

***Status:** for discussion and adoption of list of outstanding issues*

Regulatory details:

PRAC Rapporteur: Miguel-Angel Macia (ES)
PRAC Co-Rapporteur: Evelyne Falip (FR)

3.2.3. **Domperidone** (NAP)

- Review of the benefit-risk balance following notification by Belgium of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

***Status:** for discussion and adoption of list of outstanding issues*

Regulatory details:

PRAC Rapporteur: Isabelle Robine (FR)
PRAC Co-Rapporteur: Jean-Michel Dogné (BE)

3.2.4. Substances related to nicotinic acid: acipimox (NAP), xantinol nicotinate (NAP)

- Review of the benefit-risk balance following notification by Denmark of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

Status: *for discussion and adoption of list of outstanding issues (or PRAC recommendation to CMDh)*

Regulatory details:

PRAC Rapporteur: Julia Pallos (HU)
PRAC Co-Rapporteur: Line Michan (DK)

3.2.5. Strontium ranelate – OSSEOR (CAP), PROTELOS (CAP)

- Review of the benefit-risk balance following notification by the European Commission of a referral under Article 20(8) of Regulation (EC) No 726/2004, following procedural steps of Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Status: *for discussion*

Regulatory details:

PRAC Rapporteur: Ulla Wändel Liminga (SE)
PRAC Co-Rapporteur: Harald Herkner (AT)

3.3. Procedures for finalisation

3.3.1. Short-acting beta agonists:
hexoprenaline (NAP); **fenoterol** (NAP); **ritodrine** (NAP); **salbutamol** (NAP); **terbutaline** (NAP); **isoxsuprine** (NAP)

- Review of the benefit-risk balance following notification by Hungary of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

Status: *for discussion and adoption of PRAC recommendation to CMDh (or list of outstanding issues)*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)
PRAC Co-Rapporteurs: Jean-Michel Dogné (BE), Carmela Macchiarulo (IT), Jana Mladá (CZ), Julia Pallos (HU)

3.4. Re-examination procedures

3.4.1. Hydroxyethyl starch (HES), solutions for infusion (NAP)

- Re-examination procedure of the PRAC recommendation following the review of the benefit-risk balance following notification by Germany of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data

Status*: for discussion*

Regulatory details:

PRAC Rapporteur: *to be appointed*
PRAC Co-Rapporteur: *to be appointed*

3.5. Article 5(3) of Regulation (EC) No 726/2004 as amended: PRAC advice on CHMP request

None

4. Signals assessment and prioritisation[1]

4.1. New signals detected from EU spontaneous reporting systems

4.1.1. Fondaparinux – **ARIXTRA** (CAP)

- Signal of heparin induced-thrombocytopenia

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

4.1.2. Lopinavir/ritonavir – **KALETRA** (CAP), **ALUVIA** (Art 58) **Quetiapine** (NAP)

- Signal of major sedation due to drug interaction between lopinavir/ritonavir and quetiapine

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: *to be appointed*

4.1.3. Sitagliptin – **JANUVIA** (CAP), **RISTABEN** (CAP), **TESAVEL** (CAP), **XELEVIA** (CAP) **Sitagliptin**, **metformin – EFFICIB** (CAP), **JANUMET** (CAP), **RISTFOR** (CAP), **VELMETIA** (CAP) **Angiotensin-converting enzyme (ACE) inhibitors** (NAP)

- Signal of angioedema due to interaction between sitagliptin and ACE inhibitors

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: *to be appointed*

4.1.4. Tamsulosin (NAP)

- Signal of dry mouth syndrome

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: *to be appointed*

4.1.5. Thiopental (NAP)

- Signal of hypokalaemia and rebound hyperkalamaemia due to potassium imbalance

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: *to be appointed*

[1] Each signal refers to a substance or therapeutic class. The route of marketing authorisation is indicated in brackets (CAP for Centrally Authorised Products; NAP for Nationally Authorised Products including products authorised via Mutual Recognition Procedures and Decentralised Procedure). Product names are listed for reference Centrally Authorised Products (CAP) only. PRAC recommendations will specify the products concerned in case of any regulatory action required.

4.2. New signals detected from other sources

4.2.1. Human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) – CERVARIX (CAP)
Human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) – GARDASIL (CAP), **SILGARD** (CAP)

- Signal of complex regional pain syndrome (CRPS) linked to the process of vaccination

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: *to be appointed*

4.3. Signals follow-up and prioritisation

4.3.1. Levetiracetam – KEPPRA (CAP)

- Signal of syndrome of inappropriate antidiuretic hormones secretion (SIADH)

Status: *for discussion*

Regulatory details:
PRAC Rapporteur: Jean-Michel Dogné (BE)

5. Risk Management Plans

5.1. Medicines in the pre-authorisation phase

5.1.1. Afatinib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.2. Albiglutide

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.3. Aripiprazole

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.4. Budesonide, **formoterol**

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.5. Cabozantinib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.6. Canagliflozin, metformin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.7. Cobicistat

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.8. Delamanid

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.9. Empagliflozin

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.10. Ex-vivo expanded autologous human corneal epithelial cells containing stem cells

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.11. Filgrastim

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.12. Fluticasone furoate, vilanterol

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.13. Follitropin alfa

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.14. Imatinib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.15. Indacaterol, glycopyrronium bromide

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.16. Influenza vaccine (tetravalent, live attenuated, nasal)

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.17. Laquinimod

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.18. Lurasidone

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.19. Macitentan

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.20. Masitinib

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.21. Memantine

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.22. Nalfurafine

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.23. Ospemifene

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.24. Propanolol

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.25. Radium-223

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.26. Turoctocog alfa

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.1.27. Vedolizumab

- Evaluation of an RMP in the context of an initial marketing authorisation application procedure

Status: *for discussion and agreement of advice to CHMP*

5.2. Medicines already authorised

RMP in the context of a PSUR procedure

5.2.1. Abatacept – ORENCIA (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Kirsti Villikka (FI)

See also 6.1.1.

5.2.2. 5-aminolevulinic acid hydrochloride – AMELUZ (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

See also 6.1.5.

5.2.3. Belatacept – NULOJIX (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

See also 6.1.6.

5.2.4. Besilesomab – SCINTIMUN (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

See also 6.1.7.

5.2.5. Cabazitaxel – JEVTANA (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

See also 6.1.10.

5.2.6. Caffeine – PEYONA (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Harald Herkner (AT)

See also 6.1.11.

5.2.7. Omalizumab – XOLAIR (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

See also 6.1.22.

5.2.8. Plerixafor – MOZOBIL (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

See also 6.1.25.

5.2.9. Roflumilast – DALIRESP (CAP), DAXAS (CAP), LIBERTEK (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

See also 6.1.27.

5.2.10. Ticagrelor – BRILIQUE (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

See also 6.1.29.

5.2.11. Ustekinumab – STELARA (CAP)

- Evaluation of an RMP in the context of a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

See also 6.1.31.

RMP in the context of a variation

5.2.12. Aflibercept – EYLEA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Evelyne Falip (FR)

5.2.13. Anakinra – KINERET (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

5.2.14. Atanazavir – REYATAZ (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

5.2.15. Canakinumab – ILARIS (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

5.2.16. Certolizumab pegol – CIMZIA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

5.2.17. Darunavir – PREZISTA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

5.2.18. Eptacog alfa – NOVOSEVEN (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

5.2.19. Insulin human – INSUMAN (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Jean-Michel Dogné (BE)

5.2.20. Insulin lispro – HUMALOG (CAP), LIPROLOG (CAP)

- Evaluation of an RMP in the context of a worksharing variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

5.2.21. Ipilimumab – YERVOY (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

5.2.22. Paclitaxel – ABRAXANE (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

5.2.23. Pandemic influenza vaccine (N5N1) (whole virion, vero cell derived, inactivated) – PANDEMIC INFLUENZA VACCINE H5N1 BAXTER (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

5.2.24. Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) – PANDEMRIX (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

5.2.25. Posaconazole – NOXAFIL (CAP)

- Evaluation of an RMP in the context of a variation, line extension

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julia Dunne (UK)

5.2.26. Prepandemic influenza vaccine (H5N1) (whole virion, vero cell, non-adjuvanted) – VEPACEL (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Jean-Michel Dogné (BE)

5.2.27. Ranibizumab – LUCENTIS (CAP)

- Evaluation of an RMP in the context of a variation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

5.2.28. Rivastigmine – EXELON (CAP), PROMETAX (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details
PRAC Rapporteur: Evelyne Falip (FR)

5.2.29. Ustekinumab – STELARA (CAP)

- Evaluation of an RMP in the context of a variation, extension of indication

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

RMP in the context of a renewal of the marketing authorisation, conditional renewal or annual reassessment

See also Agomelatine (Thymanax, Valdoxan) under 8.1.1. , Eptotermin (Opgenra) 8.1.2. , Octocog alfa (Advate) 8.1.4. , Romiplostim (Nplate) 8.1.5.

RMP in the context of a stand-alone RMP procedure

5.2.30. Abacavir – ZIAGEN (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

5.2.31. Aripiprazole – ABILIFY (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Margarida Guimarães (PT)

5.2.32. Fentanyl – INSTANYL (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Evelyne Falip (FR)

5.2.33. Fesoterodine – TOVIAZ (CAP)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

5.2.34. Lamivudine, **zidovudine – COMBIVIR** (CAP), **LAMIVUDINE / ZIDOVUDINE VIIV** (Art 58)

- Evaluation of an RMP in the context of a stand-alone RMP procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

6. Assessment of Periodic Safety Update Reports (PSURs)

6.1. Evaluation of PSUR procedures[2]

6.1.1. Abatacept – ORENCIA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Kirsti Villikka (FI)

See also 5.2.1.

6.1.2. Aliskiren / amlodipine / hydrochlorothiazide – RASITRIO (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Carmela Macchiarulo (IT)

6.1.3. Ambrisentan – VOLIBRIS (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

6.1.4. Amifampridine – FIRDAPSE (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

[2] Where a regulatory action is recommended (variation, suspension or revocation of the terms of Marketing Authorisation(s)), the assessment report and PRAC recommendation are transmitted to the CHMP for adoption of an opinion. Where PRAC recommends the maintenance of the terms of the marketing authorisation(s), the procedure finishes at the PRAC level.
For each PRAC recommendation, in cases where other medicinal products containing the same substance are currently authorised in the EU, or subject to future authorisation procedures in the EU, the PRAC recommends that the concerned Member States and Marketing Authorisation Holders take due consideration of it.

6.1.5. 5-aminolevulinic acid hydrochloride – AMELUZ (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

See also 5.2.2.

6.1.6. Belatacept – NULOJIX (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

See also 5.2.3.

6.1.7. Besilesomab – SCINTIMUN (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

See also 5.2.4.

6.1.8. Bimatoprost, timolol – GANFORT (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Line Michan (DK)

6.1.9. C1 inhibitor, human – CINRYZE (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

6.1.10. Cabazitaxel – JEVTANA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

See also 5.2.5.

6.1.11. Caffeine – PEYONA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Harald Herkner (AT)

See also 5.2.6.

6.1.12. Canakinumab – ILARIS (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

6.1.13. Darunavir – PREZISTA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

6.1.14. Eptacog alfa – NOVOSEVEN (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

6.1.15. Ferumoxytol – RIENSO (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

6.1.16. Fondaparinux – ARIXTRA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

6.1.17. Hydroxocobalamin – CYANOKIT (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

6.1.18. Influenza vaccine (trivalent, live attenuated, nasal) – FLUENZ (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

6.1.19. Lamivudine – EPIVIR (CAP), LAMIVUDINE VIIV (Art 58)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

6.1.20. Lamivudine, zidovudine – COMBIVIR (CAP), LAMIVUDINE / ZIDOVUDINE VIIV (Art 58)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Isabelle Robine (FR)

6.1.21. Nitric oxide – INOMAX (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

6.1.22. Omalizumab – XOLAIR (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

See also 5.2.7.

6.1.23. Paliperidone – **INVEGA** (CAP), **XEPLION** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

6.1.24. Perflutren – **LUMINITY** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Almath Spooner (IE)

6.1.25. Plerixafor – **MOZOBIL** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

See also 5.2.8.

6.1.26. Pneumococcal polysaccharide conjugate vaccine (adsorbed) – **SYNFLORIX** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

6.1.27. Roflumilast – **DALIRESP** (CAP), **DAXAS** (CAP), **LIBERTEK** (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

See also 5.2.9.

6.1.28. Thyrotropin alfa – THYROGEN (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Almath Spooner (IE)

6.1.29. Ticagrelor – BRILIQUE (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

See also 5.2.10.

6.1.30. Tobramycin – TOBI PODHALER (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Sabine Straus (NL)

6.1.31. Ustekinumab – STELARA (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

See also 5.2.11.

6.1.32. Verteporfin – VISUDYNE (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Evelyne Falip (FR)

6.1.33. Ziconotide – PRIALT (CAP)

- Evaluation of a PSUR procedure

Status: *for discussion and agreement of recommendation to CHMP*

Regulatory details:
PRAC Rapporteur: Jean-Michel Dogné (BE)

6.2. Follow-up to PSUR procedures[3]

6.2.1. **Aripiprazole – ABILIFY** (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Margarida Guimarães (PT)

6.2.2. **Asenapine – SYCREST** (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

6.2.3. **Orlistat – XENICAL** (CAP)

- Evaluation of a follow-up to a PSUR procedure

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Evelyne Falip (FR)

7. Post-authorisation Safety Studies (PASS)

7.1. Protocols of post-authorisation safety studies

7.1.1. **Alipogene tiparvovec – GLYBERA** (CAP)

- Evaluation of a PASS protocol pursuant to an obligation imposed in accordance with Article 21a and 22a of Directive 2001/83/EC

Status*: for follow-up discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

7.1.2. **Colistimethate sodium – COLOBREATHE** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julia Dunne (UK)

[3] Follow up as per the conclusions of the previous PSUR procedure, assessed outside next PSUR procedure.

7.1.3. **Dapagliflozin – FORXIGA** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Qun-Ying Yue (SE)

7.1.4. **Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) – OPTAFLU** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Sabine Straus (NL)

7.1.5. **Lixisenatide – LYXUMIA** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Qun-Ying Yue (SE)

7.1.6. **Maraviroc – CELSENTRI** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Qun-Ying Yue (SE)

7.1.7. **Nomegestrol**, **estradiol – ZOELY** (CAP), **IOA** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Evelyne Falip (FR)

7.1.8. **Ocriplasmin – JETREA** (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

7.1.9. Pertuzumab – PERJETA (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Doris Stenver (DK)

7.1.10. Teduglutide – REVESTIVE (CAP)

- PRAC consultation on PASS protocol conducted pursuant an obligation imposed in accordance with Article 21a and 22a of Directive 2001/83/EC

Status: *for discussion and agreement of PRAC letter of endorsement/objection/notification*

Regulatory details:
PRAC Rapporteur: Line Michan (DK)

7.1.11. Ulipristal acetate – ELLAONE (CAP)

- PRAC consultation on a PASS protocol included in the pharmacovigilance plan of the RMP in accordance to Article 107m Directive 2001/83/EC

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Menno van der Elst (NL)

7.2. Results of post-authorisation safety studies

7.2.1. Aflibercept – ZALTRAP (CAP)

- PRAC consultation on PASS study results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Ulla Wändel Liminga (SE)

7.2.2. Betaine – CYSTADANE (CAP)

- PRAC consultation on PASS study results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Martin Huber (DE)

7.2.3. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

- PRAC evaluation of D:A:D data merger results

Status: *for discussion*

Regulatory details:

PRAC Representatives: Filip Josephson (SE), Deborah Ashby (UK)

See also 12.14.1.

7.2.4. Fentanyl – INSTANYL (CAP)

- PRAC consultation on PASS study results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Evelyne Falip (FR)

7.2.5. Octocog alfa – ADVATE (CAP)

- PRAC consultation on PASS study results

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

8. Renewals of the Marketing Authorisation, Conditional Renewals and Annual Reassessments

8.1.1. Agomelatine – THYMANAX (CAP), VALDOXAN (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)

See also under 5.2

8.1.2. Eptotermin alfa – OPGENRA (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Kirsti Villikka (FI)

See also under 5.2

8.1.3. Influenza vaccine (split virion, inactivated) – IDFLU (CAP), INTANZA (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Miguel-Angel Macia (ES)

8.1.4. Octocog alfa – ADVATE (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

See also under 5.2

8.1.5. Romiplostim – NPLATE (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Dolores Montero Corominas (ES)

See also under 5.2

8.1.6. Tafamidis – VYNDAQEL (CAP)

- PRAC consultation on an annual reassessment of the marketing authorisation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Evelyne Falip (FR)

8.1.7. Tocilizumab – ROACTEMRA (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Brigitte Keller-Stanislawski (DE)

8.1.8. Ustekinumab – STELARA (CAP)

- PRAC consultation on a renewal of the marketing authorisation

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:

PRAC Rapporteur: Julie Williams (UK)

9. Product related pharmacovigilance inspections

9.1. List of planned pharmacovigilance inspections

None

9.2. On-going or concluded pharmacovigilance inspection

Disclosure of information on results of pharmacovigilance inspections could undermine the protection of the purpose of these inspections, investigations and audits. Therefore such information is not reported in the agenda.

10. Other Safety issues for discussion requested by the CHMP or the EMA

10.1. Safety related variations of the marketing authorisation (MA)

10.1.1. **Filgrastim** (NAP), **pegfilgrastim – NEULASTA** (CAP)

- PRAC consultation on a safety-related variation, upon CHMP request

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Julie Williams (UK)

10.1.2. **Paliperidone – INVEGA** (CAP), **XEPLION** (CAP)

- PRAC consultation on a safety-related variation, upon CHMP request

Status: *for discussion and agreement of advice to CHMP*

Regulatory details:
PRAC Rapporteur: Qun-Ying Yue (SE)
PRAC Co-Rapporteur (lead): Martin Huber (DE)

10.2. Timing and message content in relation to MS safety announcements

None

10.3. Other requests

10.3.1. Tofacitinib

- PRAC consultation on a re-examination procedure of an initial marketing authorisation upon CHMP request

Status: *for discussion and agreement of advice to CHMP*

11. Other Safety issues for discussion requested by the Member States

11.1. Safety related variations of the marketing authorisation

None

11.2. Renewals of the Marketing Authorisation

None

11.3. Other requests

None

12. Organisational, regulatory and methodological matters

12.1. Mandate and organisation of the PRAC

None

12.2. Pharmacovigilance audits and inspections

None

12.3. Periodic Safety Update Reports & Union Reference Date (EURD) List

12.3.1. Union Reference Date List

12.3.1.1. Consultation on the draft List, version July 2013

Status: *for discussion and agreement of the list*

12.4. Signal Management

12.4.1. Signal Management

- Feedback from Signal Management Review Technical (SMART) Working Group

Status: for information

12.5. Adverse Drug Reactions reporting and additional reporting

12.5.1. List of Product under Additional Monitoring

12.5.1.1. Consultation on the draft List, version July 2013

Status: *for discussion and agreement of the list*

12.6. EudraVigilance Database

None

12.7. Risk Management Plans and Effectiveness of risk Minimisations

12.7.1. Progressive multifocal leukoencephalopathy (PML): possibilities for monitoring and labelling

- Development of an evidence-based strategy

Status: *for discussion*

12.8. Post-authorisation Safety Studies

12.8.1. Patient Registries

- Proposal to initiate the process of encouraging and supporting joint disease based-registries

Status*: for discussion*

12.9. Community Procedures

None

12.10. Risk communication and Transparency

None

12.11. Continuous pharmacovigilance

None

12.12. Interaction with EMA Committees and Working Parties

12.12.1. Committees

None

12.12.2. Working Parties

12.12.2.1. Vaccine Working Party (VWP)

- Explanatory note on the withdrawal of the 'Note for Guidance on Harmonisation of Requirements for Influenza Vaccines' (CPMP/BWP/214/96) and of the Core SmPC/PIL for inactivated seasonal influenza vaccines (CMDh/128/2003/Rev5 and CMDh/129/2008/Rev3)

Status: *for adoption*

12.13. Interaction within the EU regulatory network

None

12.14. Contacts of the PRAC with external parties and interaction of the EMA with interested parties

12.14.1. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

- PRAC evaluation of D:A:D data merger results

Status: *for discussion*

See also 7.2.3.

12.14.2. Medication errors

- Workshop outcome: implementation plan and deliverables

Status*: for discussion*

13. Any other business

None